ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag law genetics genomics

Surpassing the Law of Averages
Jeffrey M. Perkel | Sep 1, 2009 | 7 min read
By Jeffrey M. Perkel Surpassing the Law of Averages How to expose the behaviors of genes, RNA, proteins, and metabolites in single cells. By necessity or convenience, almost everything we know about biochemistry and molecular biology derives from bulk behavior: From gene regulation to Michaelis-Menten kinetics, we understand biology in terms of what the “average” cell in a population does. But, as Jonathan Weissman of the University of Califo
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Company Offers Free Whole-Genome Sequencing for Data Sharers
Shawna Williams | Nov 15, 2018 | 2 min read
Nebula Genomics is among the first blockchain-based companies to reward users for contributing personal data for research.
A Flood in Genomics
Brendan Maher | Nov 25, 2001 | 9 min read
Nine months have passed since draft sequences of the human genome were first published.1,2 One human gestation period later, the genome, as deciphered by the International Human Genome Sequencing Consortium, still screams toward its projected Spring 2003 finish date. "The trajectory we're on for meeting that goal is precisely on target," assures Francis Collins, director, National Human Genome Research Institute (NHGRI) and spokesperson for the largest public biological science project in histor
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
Research Briefs
Maria Anderson | Oct 19, 2003 | 4 min read
Research Briefs New Genes: The Ears Have 'Em; The Worker, The Soldier, The Candlestick Maker; For Genomes Without Borders, Biobanks Unite New genes: The ears have 'em While scouring a new cDNA library, researchers in the Netherlands discovered 80 novel expressed-sequence tags, including 25 preferentially expressed in human fetal cochlea.1 The researchers from the University Medical Center in Nijmegen (UMCN) found that 155 ESTs map to loci for nonsyndromic deafness, which is not associated
'Identical' cells? Not so much
Megan Scudellari | Jul 28, 2010 | 3 min read
Genetically identical cells may be far more different than previously believed. Published this week in linkurl:Science,;http://www.sciencemag.org/ researchers find striking variation in levels of gene expression among individual, genetically identical E. coli, seemingly the result of simple chance. "The paper is quite rich," said linkurl:Sanjay Tyagi,;http://www.phri.org/research/res_pityagi.asp a molecular biologist at New Jersey Medical School who was not involved in the research. "People thi
Clinton, Blair Stoke Debate on Gene Data
Ricki Lewis | Apr 2, 2000 | 7 min read
President Bill Clinton and British Prime Minister Tony Blair's brief statement of March 14 supporting free access to human genome information unleashed a slew of clichés, including "too little too late" and "water under the bridge." But initial misinterpretation of the statement led to a temporary slide in biotech stocks. By the end of the day, Celera Genomics Corp. of Rockville, Md., had dropped 19 percent, while Incyte Pharmaceuticals of Palo Alto, Calif., plummeted 27 percent. Even thoug
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Epigenetics and Society
Andrew D. Ellington | Mar 1, 2011 | 3 min read
Did Erasmus Darwin foreshadow the tweaking of his grandson’s paradigm?

Run a Search

ADVERTISEMENT